

PATIENT ENROLLMENT SECTION

Taltz® (ixekizumab) Pediatric

PP-RC-US-2030 12/2023 ©Lilly USA, LLC 2023. All rights reserved.

PUBLISHED 12/2023

OFFICE: Complete the entire form and submit pages 1-4 to Taltz Together™ via fax at 1-844-344-8108 or upload online at https://patientsupportnow.org and code: 8443448108. For assistance, call 1-844-TALTZ-NOW (1-844-825-8966), Monday-Friday 8am - 10pm ET.

Section 1:	Patient and Authorized Representative Information
------------	---

Patient Name (First, MI, Last)	DOB (MM/DD/YYYY)
Gender ☐ M ☐ F Patient State of Residence	
Authorized Representative Name (First, MI, Last)	DOB (MM/DD/YYYY)
Relationship to Patient	
Address City	State Zip
US or Puerto Rico Resident ☐ Yes ☐ No Gender ☐ M ☐ F Preferred Langua	ge ☐ English ☐ Spanish ☐ Other
Phone* *By checking the box, I agree to receive automated marketing calls and texts from and am not required to provide my number as a condition of receiving goods and service By checking the box, I agree to be contacted to: provide feedback on my experience my story; and, to participate in market and medical research studies about products	s. Message and data rates may apply. with the related products, services, and programs; to share
Must select one of the following: No Insurance Coverage Copy of Policyholder's Insurance Car	rd (Front and Back) Is Attached \Box Provide Information Below
Primary Prescription Insurance Company	
Insurance Company Phone # Cardholder N	Name
Policy/ID Group #	
RX BIN PCN	
Please select which options you would like to enroll in by checking the corresponding checking checking the corresponding checking checkin	kboxes below. By enrolling in any of these services
below, you are agreeing to the Terms of Participation and enrolling in Taitz Together''.	
below, you are agreeing to the Terms of Participation and enrolling in Taltz Together™. ☐ 1. <u>Taltz® Savings Card</u>	
I	ible)
☐ 1. <u>Taltz® Savings Card</u>	
1. Taltz® Savings Card SAVINGS CARD ELIGIBILITY (must confirm the below statements in order to be eligi	age uding, without limitation, Medicaid, Medicare, Medicare
□ 1. Taltz® Savings Card SAVINGS CARD ELIGIBILITY (must confirm the below statements in order to be eligit of the United States or Puerto Rico who is 18 years of of the United States or Puerto Rico who is 18 years of or I confirm that I am NOT enrolled in a government-funded prescription program, included prescription prescription prescription prescription prescriptio	age uding, without limitation, Medicaid, Medicare, Medicare
□ 1. Taltz® Savings Card SAVINGS CARD ELIGIBILITY (must confirm the below statements in order to be eligit of the United States or Puerto Rico who is 18 years of or confirm that I am NOT enrolled in a government-funded prescription program, inclurant D, Medigap, DoD, VA, TRICARE®/CHAMPUS, or any state patient or pharmaceur	age uding, without limitation, Medicaid, Medicare, Medicare



contact us at 1-844-TALTZ-NOW (1-844-825-8966) Mon-Fri, 8am -10pm ET. For information about Lilly's privacy practices, please see our Privacy Statement at https://privacynotice.lilly.com.



PP-RC-US-2030 12/2023 ©Lilly USA, LLC 2023. All rights reserved.

PUBLISHED 12/2023

OFFICE: Complete the entire form and submit pages 1-4 to Taltz Together™ via fax at 1-844-344-8108 or upload online at https://patientsupportnow.org and code: 8443448108. For assistance, call 1-844-TALTZ-NOW (1-844-825-8966), Monday-Friday 8am − 10pm ET.

By enrolling in the Taltz Savings Card Program ("Program") and using the Taltz Savings Card ("Card"), you attest that you meet the eligibility criteria, agree to, and will comply with the terms and conditions described below:

Card Eligibility:

- (1.) You have been prescribed Taltz[®] (ixekizumab) consistent with FDA approved product labeling
- (2.) You are enrolled in a commercial drug insurance plan
- (3.) You are not enrolled in any state, federal, or government funded healthcare program, including, without limitation, Medicaid, Medicare, Medicare Part D, Medicare Advantage, Medigap, DoD, VA, TRICARE®/CHAMPUS, or any state prescription drug assistance program.
- (4.) You are a resident of the United States or Puerto Rico
- (5.) You are 18 years of age or older

Card Terms and Conditions:

For patients with commercial drug insurance coverage for Taltz: You must have commercial drug insurance that covers Taltz and a prescription consistent with FDA-approved product labeling to pay as little as \$5 for a 1-month prescription fill of Taltz. Month is defined as 28-days and up to 3 pens. Card must be first used by no later than 12/31/2024. Card savings are subject to a maximum monthly savings of wholesale acquisition cost plus usual and customary pharmacy charges and a separate maximum annual savings of up to \$9,450 per calendar year. Card may be used for up to a maximum of 14 prescription fills per calendar year and up to a maximum of 24 prescription fills over the lifetime of the Program, subject to the previously stated maximum monthly and annual savings limit. Participation in the Program requires a valid patient HIPAA authorization upon enrollment into the Program. Subject to Lilly USA, LLC's right to terminate, rescind, revoke, or amend Card eligibility criteria and/or Card terms and conditions which may occur at Lilly's sole discretion, without notice, and for any reason, Card expires and savings end on 12/31/2026 or 24 months after you first use the Card, whichever comes first.

For patients with commercial drug insurance who do not have coverage for Taltz: You must have commercial drug insurance that does not cover Taltz and a prescription consistent with FDA-approved product labeling to pay as little as \$25 for a 1-month supply of Taltz. Month is defined as 28-days and up to 3 pens. Card savings are subject to a maximum monthly savings and a separate maximum annual savings. Card may be used for up to a maximum of 14 prescription fills per year and up to a maximum 24 prescription fills over the lifetime of the Program, subject to the maximum monthly and annual savings limit. Card must be first used by no later than 12/31/2024. Participation in the Program requires submission of a prior authorization (PA) prior to the first prescription fill. If coverage is denied, an appeal must be submitted prior to 5th month prescription fill. To remain eligible for the Program, a new PA, appeal, or medical exception must be submitted prior to the 13th prescription fill and as required by Lilly at its sole discretion. Participation in the Program requires a valid patient HIPAA authorization to remain in the Program. Subject to Lilly USA, LLC's right to terminate, rescind, revoke, or amend Card eligibility criteria and/or Card terms and conditions, which may occur at Lilly's sole discretion, without notice, and for any reason, Card expires and savings end on 12/31/2026 or 24 months after you first use the Card, whichever comes first.

Additional Program Terms and Conditions

If you have an insurance plan that is participating in an alternate funding program ("AFP") (examples include, but are not limited to, ImpaxRX, Payer Matrix, SHARx, Script Sourcing, and Paydhealth) that requires you to apply to the Taltz Savings Card Program or otherwise pursue specialty drug prescription coverage through an alternate funding vendor as a condition of, requirement for, or prerequisite to coverage of Taltz, you are not eligible for and are prohibited from using the Taltz Savings Card Program. AFPs include programs where coverage, reimbursement, or patient out of pocket costs for a product in some way vary based on the availability of a manufacturer co-pay program. AFPs may modify, delay, deny, restrict, or withhold insurance benefits or coverage from patients, or exclude Lilly products from coverage contingent upon a member's use of Taltz Savings Card Program. You agree to inform Taltz Savings Card Program if you are or become a member of such an alternative funding program. You are responsible for any applicable taxes, fees, and any amount that exceeds the monthly or annual maximum Card savings. Monthly and annual maximum savings are set at Lilly's sole and absolute discretion and may be changed with or without notice at any time for any reason. At its sole discretion and with or without notice, Lilly may reduce, eliminate, or otherwise modify the Card savings for any reason, including but not limited to if your commercial drug insurance plan imposes additional requirements which limits or prevents you from receiving coverage for Taltz, only allows partial coverage for Taltz, removes coverage for Taltz and requires you to utilize the Card, does not provide a material level of financial assistance for the cost of Taltz, or does not apply Card payments to satisfy your co-payment, deductible, or coinsurance for Taltz. Card savings are not valid for: Massachusetts residents if an AB-rated generic equivalent is available; California residents if an FDA-approved therapeutic equivalent is available. You must meet the Card eligibility criteria, terms and conditions every time you use the Card. If at any time you begin receiving drug coverage under any state, federal, or government funded healthcare program, you understand that you will no longer be eligible for the Taltz Savings Card and agree to call the Taltz Savings Card Program at 1-844-825-8966 to stop participation. Card activation is required. No party may seek reimbursement from your health insurance, any third party, or any health savings, flexible spending, or other healthcare reimbursement accounts, for any amount of the savings received through the Card. By utilizing the Card, you agree that if you are required to do so under the terms of your insurance coverage for this prescription or are otherwise required to do so by law, you will notify your Insurance Carrier of your redemption of the Card. Card savings cannot be combined or utilized with any other program, discount, discount card, cash discount card, coupon, incentive, or similar offer involving Taltz. You agree that this Card savings is intended solely for the benefit of you, the patient, and that the Card benefits are nontransferable. It is prohibited for any person to sell, purchase, or trade; or to offer to sell, purchase, or trade, or to counterfeit the Card. The Card is not insurance. Lilly has the sole right to interpret and apply Card eligibility criteria, and terms and conditions. Card eligibility, and terms and conditions may be terminated, rescinded, revoked, or amended by Lilly at any time without notice and for any reason, Eligibility criteria, and terms and conditions for the Taltz Savings Card Program may change from time to time; the most current version can be found at https://www.Taltz.com. You may be required to obtain a new Card, including if any Card terms and conditions have been terminated, rescinded, revoked, or amended by Lilly. Card void where prohibited by law. Subject to Lilly's right to terminate, rescind, revoke or amend Card eligibility criteria and/or Card terms and conditions, which may occur at Lilly's sole discretion, without notice, and for any reason, the Card expires and savings end on 12/31/2026 or 24 months after you first use the Card, whichever comes first.





PATIENT HIPAA AUTHORIZATION

OFFICE: Complete the entire form and submit pages 1-4 to Taltz Together™ via fax at 1-844-344-8108 or upload online at https://patientsupportnow.org and code: 8443448108. For assistance, call 1-844-TALTZ-NOW (1-844-825-8966), Monday-Friday 8am − 10pm ET.

PP-RC-US-2030 12/2023 ©Lilly USA, LLC 2023. All rights reserved.

PUBLISHED 12/2023

Before Taltz Together[™] can start helping you, Lilly may ask for some information about you and your health from your Health Care Entities (as defined below). This is known as your Protected Health Information, or PHI. By signing this form, you understand and agree that your PHI may be shared with or used by Lilly as explained below.

PHI includes information like:

- Your health insurance or benefits, including how much coverage you have
- All records about your treatment
- Whether you're staying on your medicine or treatment

If you agree, your PHI may be shared by these entities (together "Health Care Entities"):

- Your doctors and other healthcare providers
- Your healthcare plan or health insurance company
- Clearinghouses or other agents
- Your pharmacy
- Others who might have your PHI on behalf of your healthcare providers, pharmacies and healthcare plans

Your PHI is used in ways like these:

- To learn how much of your Lilly treatment is covered by your insurance
- To help you find other ways to afford your treatment
- To track your use of your Lilly treatment
- To share information with your healthcare provider
- To make sure that you receive high-quality services from the program
- To measure program performance and make program improvements
- Internal Lilly use of data to drive business decisions and metrics on hub performance
- Reports to our sales force regarding HCP use of hub services
- Conversations/messages to your HCP regarding trends and hub performance

Other things you should know about sharing and using your PHI:

- We only ask for and share the PHI that we need to provide the benefits you want. We do not ask for any PHI that we do not need, but we may
 receive some in the health records sent to us. Your PHI will be released to Eli Lilly and Company and Lilly USA, LLC and its affiliates, agents,
 representatives, and service providers (together "Lilly").
- You don't have to give permission to share your PHI with Lilly to receive treatment from your healthcare providers, your prescription from your pharmacy, or benefits from your healthcare plan, but Taltz Together™ may not be able to help you without it
- After your PHI has been shared, it may no longer be covered by federal and state privacy laws (such as HIPAA), and it may be shared again with others by Lilly
- Your signed permission to share and use your PHI lasts for 3 years from the date of your signature unless you are a resident of Maryland,
 Maine, or Montana, in which case the permission will last for 1 year from the date of your signature. In either case, you may revoke your permission before then by writing to PO Box 221349, Charlotte, NC 28222, which will preclude reliance on the authorization after the date your written revocation is received
- Your healthcare providers (such as pharmacies) may be paid by us in exchange for sharing your PHI. They may also be paid by us to use your PHI to provide services, such as contacting you about Lilly products
- You can stop sharing your PHI with us or change what you share by calling us at 1-844-TALTZ-NOW (1-844-825-8966) or by writing us at PO Box 221349, Charlotte, NC 28222
- Your cancellation or revocation of this Authorization will be effective when your Health Care Entities receive notice of your
 cancellation or revocation, and will not apply to any information shared with Lilly by your Health Care Entities prior to the time
 those Health Care Entities receive notice

By signing this form, I attest that I have read and agree to the Patient HIPAA Authorization. By signing this Authorization, I represent that I am the Authorized Representative for the Pediatric Patient. I understand I am entitled to a copy of this signed Authorization.



Signature of Authorized Representative	Date Signed (MM/DD/YYYY)
Printed Name of Authorized Representative	DOB (MM/DD/YYYY)
Not signing this form will result in an incomplete submission and a delay in requested services	





PRESCRIBER ENROLLMENT SECTION

Taltz® (ixekizumab) Pediatric

PP-RC-US-2

OFFICE: Complete the entire form and submit pages 1-4 to Taltz Together™ via fax at 1-844-344-8108 or upload online at https://patientsupportnow.org and code: 8443448108. For assistance, call 1-844-TALTZ-NOW (1-844-825-8966).

Prescriber information

Section 5: Diagnosis

HCP Service Selection & Prescription

Benefits Investigation Support (select one choice) Specialty Pharmacy Conducted Benefits Investigation—Specialty Pharmacy where prescription was sent Specialty Pharmacy Conducted Benefits Investigation—Specialty Pharmacy where prescription was sent Specialty Pharmacy Conducted Benefits Investigation—Specialty Pharmacy where prescription was sent Specialty Pharmacy Phone Number Lilly Conducted Benefits Investigation—Taliz Together ^{14*} will research the Patient's insurance and in-network Specialty Pharmacy options to help identify the lowes duct-of pocket cost available for Taliz* and will forward the prescription to the Specialty Pharmacy has the Patient's behalf. If CHECKED, MUST FILL OUT PRESCRIPTION SECTION BELOW Taliz* (Ixekizumab) Prescription—Fill out corresponding prescription below and sign at the bottom of page Dosing for Plaque Psoriasis (ICD-10 L40.0), based on Patient weight Weight Device Type Dosing (S0 mg/ml.) Im. Inj Maintenance Dose: 1 x 80 mg by subcutaneous injection Day 1 pen/syringe 28 pen and sign of the prescription below and sign at the bottom of page 28 pen and an analysis of the prescription below and sign at the bottom of page 28 pen and an analysis of the prescription below and sign at the bottom of page 28 pen and an analysis of the pen sign of the pen s	-me (F	irst Last)_		NPI #			
### State Zip ### State Zip ### Office Contact Name ### Office Contact Email ### Office Pharmacy Onders to Email Emai	-	· ·					
fine Contact Rame Group Tax ID							
### Specialty Pharmacy Conducted Benefits Investigation—Specialty Pharmacy where prescription was sent. Specialty Pharmacy Conducted Benefits Investigation—Specialty Pharmacy where prescription was sent.							
atient Name (First, MI, Last)							
agnosis: Plaque Psoriasis (ICD-10 Code: L40.0)					ים Tax ID		
Plaque Psoriasis (ICD-10 Code: L40.0)							
Plaque Psoriasis (ICD-10 Code: L40.0)		•	•		,	•	
Plaque Psoriasis (ICD-10 Code: L40.0) ■ Benefits Investigation Support (select one choice) □ Specialty Pharmacy Conducted Benefits Investigation—Specialty Pharmacy where prescription was sent				City 51	tate	Zip	
Benefits Investigation Support (select one choice) Specialty Pharmacy Conducted Benefits Investigation—Specialty Pharmacy where prescription was sent. Specialty Pharmacy Phone Number Lilly Conducted Benefits Investigation—Taltz Together** will research the Patient's insurance and in-network Specialty Pharmacy options to help identify the lowest out-of-pocket cost available for Taltz* and will forward the prescription to the Specialty Pharmacy that the Patient selects. A Taltz Togethe representative will help triage and troubleshoot access issues on the Patient's behalf. IF CHECKED, MUST FILL OUT PRESCRIPTION SECTION BELOW Taltz* (Kockizumab) Prescription — Fill out corresponding prescription below and sign at the bottom of page Dosing for Plaque Psoriasis (ICD-10 L40.0), based on Patient weight Weight Device Type Dosing Quantity Days Supply Refill Starting Dose: 2 x 80 mg each (160 mg total) 2 pens/syringes 28 0 1 1 1 1 1 1 1 1 1	ugii-e		Penriasis (ICD-10 Code: L40.0)				
Specialty Pharmacy Conducted Benefits Investigation—Specialty Pharmacy where prescription was sent. Specialty Pharmacy Phone Number		1 1 2 242 .	1 30110313 (1012 20 00000				_
Specialty Pharmacy Conducted Benefits Investigation—Specialty Pharmacy where prescription was sent. Specialty Pharmacy Phone Number □ Lilly Conducted Benefits Investigation—Taltz Together™ will research the Patient's insurance and in-network Specialty Pharmacy options to help identify the lowest out-of-pocket cost available for Taltz² and will forward the prescription to the Specialty Pharmacy that the Patient selects. A Taltz Together representative will help triage and troubleshoot access issues on the Patient's behalf. IF CHECKED, MUST FILL OUT PRESCRIPTION SECTION BELOW Taltz² (ixekizumab) Prescription — Fill out corresponding prescription below and sign at the bottom of page Dosing for Plaque Psoriasis (ICD-10 L40.0), based on Patient weight Wei							
Lilly Conducted Benefits Investigation—Taltz Together Will research the Patient's insurance and in-network Specialty Pharmacy options to help identify the lowest out-of-pocket cost available for Taltz* and will forward the prescription to the Specialty Pharmacy that the Patient selects. A Taltz Togethe representative will help triage and throubleshoot access issues on the Patient's behalf. IF CHECKED, MUST FILL OUT PRESCRIPTION SECTION BELOW Taltz** (ixekizumab) Prescription — Fill out corresponding prescription below and sign at the bottom of page Dosing for Plaque Psoriasis (ICD-10 L40.0), based on Patient weight Weight		Benefits In	vestigation Support (select one	choice)			
Lilly Conducted Benefits Investigation—Taltz Together** will research the Patient's insurance and in-network Specialty Pharmacy options to help identify the lowest out-of-pocket cost available for Taltz* and will forward the prescription to the Specialty Pharmacy that the Patient selects. A Taltz Togethe representative will help triage and troubleshoot access issues on the Patient's behalf. IF CHECKED, MUST FILL OUT PRESCRIPTION SECTION BELOW Taltz** (ixekizumab) Prescription — Fill out corresponding prescription below and sign at the bottom of page Dosing for Plaque Psoriasis (ICD-10 L40.0), based on Patient weight Weight Device Type Dosing Quantity Days Supply Refill If > 50 kg [10 lbs] Prefilled syringe (80 mg/mL) 1mL inj Subcutaneous injection on Day 1 Maintenance Dose: 1 x 80 mg by subcutaneous Injection on Day 1 Pen/syringe 28 Dosing Prefilled syringe (80 mg/mL) 1mL inj Maintenance Dose: 1 x 80 mg by subcutaneous injection Day 1 1 syringe 28 Dosing If <25 kg Must use: Starting Dose: 1 x 40 mg by subcutaneous injection Day 1 1 syringe 28 Dosing Injection every 4 weeks (thereafter) Indiantenance Dose: 1 x 40 mg by subcutaneous injection Day 1 1 syringe 28 Dosing Injection every 4 weeks (thereafter) Indiantenance Dose: 1 x 40 mg by subcutaneous injection Day 1 1 syringe 28 Dosing Injection every 4 weeks (thereafter) Indiantenance Dose: 1 x 40 mg by subcutaneous injection Day 1 1 syringe 28 Dosing Injection every 4 weeks (thereafter) Indiantenance Dose: 1 x 40 mg by subcutaneous injection Day 1 1 syringe 28 Dosing Injection every 4 weeks (thereafter) Indiantenance Dose: 1 x 40 mg by subcutaneous injection Day 1 1 syringe 28 Dosing Injection every 4 weeks (thereafter) Indiantenance Dose: 1 x 40 mg by subcutaneous injection Day 1 1 syringe 28 Dosing Injection every 4 weeks (thereafter) Indiantenance Dose: 1 x 40 mg by subcutaneous injection Day 1 1 syringe 28 Dosing Injection every 4 weeks (thereafter) Indiantenance Dose: 1 x 40 mg by subcutaneous injection Day 1 1 syringe 28 Dosing Injection every 4			,				
identify the lowest out-of-pocket cost available for Taltz* and will forward the prescription to the Specialty Pharmacy that the Patient selects. A Taltz Togethe representative will help triage and troubleshoot access issues on the Patient's behalf. IF CHECKED, MUST FILL OUT PRESCRIPTION SECTION BELOW Taltz* (ixekizumab) Prescription — Fill out corresponding prescription below and sign at the bottom of page Dosing for Plaque Psoriasis (ICD-10 L40.0), based on Patient weight Weight Device Type Dosing Quantity Days Supply Refill If 5 0 kg (110 lbs) Patient Subcutaneous injection on Day 1 Must select one: Subcutaneous Injection on Day 1 Must select One: Subcutaneous Injection on Day 1 Must select One: Subcutaneous Injection on Day 1 Must use: Starting Dose: 1 x 80 mg by subcutaneous injection Day 1 1 pen/syringe 28 Dosing Dose: 1 x 80 mg by subcutaneous injection Day 1 1 syringe 28 Dosing Must use: Starting Dose: 1 x 80 mg by subcutaneous injection Day 1 1 syringe 28 Dosing Dose: 1 x 80 mg by subcutaneous injection Day 1 1 syringe 28 Dosing Dose: 1 x 80 mg by subcutaneous injection Day 1 1 syringe 28 Dosing Dose: 1 x 80 mg by subcutaneous injection Day 1 1 syringe 28 Dosing Dose: 1 x 80 mg by subcutaneous injection Day 1 1 syringe 28 Dose:		Specialty	/ Pharmacy Phone Number				
identify the lowest out-of-pocket cost available for Taltz* and will forward the prescription to the Specialty Pharmacy that the Patient selects. A Taltz Togethe representative will help triage and troubleshoot access issues on the Patient's behalf. IF CHECKED, MUST FILL OUT PRESCRIPTION SECTION BELOW Taltz* (ixekizumab) Prescription — Fill out corresponding prescription below and sign at the bottom of page Dosing for Plaque Psoriasis (ICD-10 L40.0), based on Patient weight Weight Device Type Dosing Quantity Days Supply Refill If 5 0 kg (110 lbs) Patient Subcutaneous injection on Day 1 Must select one: Subcutaneous Injection on Day 1 Must select One: Subcutaneous Injection on Day 1 Must select One: Subcutaneous Injection on Day 1 Must use: Starting Dose: 1 x 80 mg by subcutaneous injection Day 1 1 pen/syringe 28 Dosing Dose: 1 x 80 mg by subcutaneous injection Day 1 1 syringe 28 Dosing Must use: Starting Dose: 1 x 80 mg by subcutaneous injection Day 1 1 syringe 28 Dosing Dose: 1 x 80 mg by subcutaneous injection Day 1 1 syringe 28 Dosing Dose: 1 x 80 mg by subcutaneous injection Day 1 1 syringe 28 Dosing Dose: 1 x 80 mg by subcutaneous injection Day 1 1 syringe 28 Dosing Dose: 1 x 80 mg by subcutaneous injection Day 1 1 syringe 28 Dose:		□ I illv Cor	ducted Renefits Investigation-Talt	to Together™ will research the Patient's insurance and in-n	otwork Specialty F	Pharmacy ontion	s to help
Taltz® (ixekizumab) Prescription — Fill out corresponding prescription below and sign at the bottom of page Dosing for Plaque Psoriasis (ICD-10 L40.0), based on Patient weight Weight Device Type		identify the	e lowest out-of-pocket cost available for Taltz	z® and will forward the prescription to the Specialty Pharm	acy that the Patier	nt selects. A Taltz	z Together
Dosing for Plaque Psoriasis (ICD-10 L40.0), based on Patient weight Weight Device Type							
Weight Device Type Dosing Quantity Days Supply Refil			Taltz® (ixekizumab) Prescription	n — Fill out corresponding prescription below and sign	at the bottom of	page	
Weight Device Type Dosing Quantity Days Supply Refil		Desing for	Clares Booriogie (ICD-10 I 40 0), based or	- Dakinak unimbe			
If 5 50 kg (110 lbs)		Dusing io	'laque rsoriasis (IOD-10 E-10.0), Ducca	1 Patient weight			
City				·			
Maintenance Dose: 1 x 80 mg by subcutaneous 1 pen/syringe 28				<u> </u>			Refills
Starting Dose: 1 x 80 mg by subcutaneous injection Day 1 1 syringe 28 0 maintenance Dose: 1 x 80 mg by subcutaneous injection Day 1 1 syringe 28 1 syringe 2		If > 50 kg	Must select one:	☐ Starting Dose: 2 x 80 mg each (160 mg total) subcutaneous injection on Day 1		28	
(55 lbs) roga and osing (55 lbs) to 50 kg (110lbs)	" must	If > 50 kg	Must select <u>one:</u> Prefilled syringe (80 mg/mL) 1mL inj	☐ Starting Dose: 2 x 80 mg each (160 mg total) subcutaneous injection on Day 1 ☐ Maintenance Dose: 1 x 80 mg by subcutaneous	2 pens/syringes	28	
ill out the below if the patient weight is < 50 kg Product to be shipped to: Prescriber's Office Administering Provider's Office (fill out information below) Name (First, Last) Office/Hospital/Other Name Address Phone Taltz® doses of 20 mg or 40 mg must be prepared and administered by a qualified Healthcare Provider using aseptic technique Prior Treatment Failures, Contraindications, Intolerances, or Allergies (select all that apply) Phototherapy ENBREL® STELARA® Other(s) Signing below, I certify: 1) The therapy is medically necessary and that this information is accurate to the best of my knowledge; 2) I am disclosing this information to Eli Lilly and Company, Lilly US (c), their affiliates, agents, representatives, business partners, and service providers (together "Lilly") to help enable treatment for this Patient; 3) The Patient is aware of, has consented to, and has dy disclosure of their information to Lilly so that Lilly may contact the Patient to further enable services for those purposes and that such consent and direction applies to disclosures made through the rescription complies with my state specific prescribing requirements and I appoint Lilly as my agent for the limiting falts® purposes of conveying this prescription by facsimile only to the dispensing pharma deterstand that by signing this form, I am requesting support from Eli Lilly and Company pharma deterstand that by signing this form, I am requesting support from Eli Lilly and Company for Patients requirement falts pharma dicerstand that by signing this form, I am requesting support from Eli Lilly and Company for Patients requirements and appoint Lilly as my agent for the limited purposes of conveying this prescription by facsimile only to the dispensing pharma dicerstand that by signing this form, I am requesting support from Eli Lilly and Company for Patients therapy and the support Lilly as my agent for the limited proposes of conveying this prescription by facsimile only to the dispensing pharma	elect a	If > 50 kg (110 lbs)	Must select <u>one:</u> Prefilled syringe (80 mg/mL) 1mL inj Auto Injector (80 mg/mL) 1mL inj Must use:	□ Starting Dose: 2 x 80 mg each (160 mg total) subcutaneous injection on Day 1 □ Maintenance Dose: 1 x 80 mg by subcutaneous injection every 4 weeks (thereafter) □ Starting Dose: 1 x 80 mg by subcutaneous injection Day 1	2 pens/syringes 1 pen/syringe	28 28	0
If < 25 kg (55 lbs) Must use: Prefilled syringe (80 mg/mL) 1mL inj Maintenance Dose: 1 x 20 mg subcutaneous injection Day 1 1 syringe 28 28 28 28 28 28 28 2	ou must elect a evice /pe and	If > 50 kg (110 lbs)	Must select <u>one:</u> Prefilled syringe (80 mg/mL) 1mL inj Auto Injector (80 mg/mL) 1mL inj Must use:	□ Starting Dose: 2 x 80 mg each (160 mg total) subcutaneous injection on Day 1 □ Maintenance Dose: 1 x 80 mg by subcutaneous injection every 4 weeks (thereafter) □ Starting Dose: 1 x 80 mg by subcutaneous injection Day 1 □ Maintenance Dose: 1 x 40 mg by subcutaneous	2 pens/syringes 1 pen/syringe 1 syringe	28 28 28	0
every 4 weeks (thereafter) Sylinge 20	elect a evice	If > 50 kg (110 lbs) If 25 kg (55 lbs) to 50 kg	Must select <u>one:</u> Prefilled syringe (80 mg/mL) 1mL inj Auto Injector (80 mg/mL) 1mL inj Must use:	□ Starting Dose: 2 x 80 mg each (160 mg total) subcutaneous injection on Day 1 □ Maintenance Dose: 1 x 80 mg by subcutaneous injection every 4 weeks (thereafter) □ Starting Dose: 1 x 80 mg by subcutaneous injection Day 1 □ Maintenance Dose: 1 x 40 mg by subcutaneous	2 pens/syringes 1 pen/syringe 1 syringe	28 28 28	0
Product to be shipped to: Prescriber's Office Administering Provider's Office (fill out information below) Patient Name (First, Last) Office/Hospital/Other Name Address Phone Fax Taltz® doses of 20 mg or 40 mg must be prepared and administered by a qualified Healthcare Provider using aseptic technique Prior Treatment Failures, Contraindications, Intolerances, or Allergies (select all that apply) No previous biologic or systemic agent Phototherapy Phototherapy STELARA® Other(s) STELARA® Other(s) Visigning below, I certify: 1) The therapy is medically necessary and that this information is accurate to the best of my knowledge; 2) I am disclosing this information to Eli Lilly and Company, Lilly US C., their affiliates, agents, representatives, business partners, and service providers (together "Lilly") to help enable treatment for this Patient; 3) The Patient is aware of, has consented to, and has do visicoloure of their information to Lilly so that Lilly may contact the Patient to further enable sources for those purposes and that such consent and direction applies to disclosures made through the ration of the Patient's therapy; 4) I will not seek reimbursement from any third party for the support Lilly provides; and 5) I am licensed to prescribe the prescription medication identified in this form escription complies with my state specific prescribing requirements and I appoint Lilly as my agent for the limited purposes of conveying this prescription prescription pharma derstand that by signing this form, I am requesting support from Eli Lilly and Company for Patients' receiving Taltz® pursuant to an FDA approved indication. PRESCRIBER SIGNATURE: PRESCRI	elect a evice pe and	If > 50 kg (110 lbs) If 25 kg (55 lbs) to 50 kg (110lbs) If < 25 kg	Must select one: Prefilled syringe (80 mg/mL) 1mL inj Auto Injector (80 mg/mL) 1mL inj Must use: Prefilled syringe (80 mg/mL) 1mL inj Must use:	□ Starting Dose: 2 x 80 mg each (160 mg total) subcutaneous injection on Day 1 □ Maintenance Dose: 1 x 80 mg by subcutaneous injection every 4 weeks (thereafter) □ Starting Dose: 1 x 80 mg by subcutaneous injection Day 1 □ Maintenance Dose: 1 x 40 mg by subcutaneous injection every 4 weeks (thereafter) □ Starting Dose: 1 x 40 mg by subcutaneous injection Day 1	2 pens/syringes 1 pen/syringe 1 syringe 1 syringe	28 28 28 28	0
Product to be shipped to: Prescriber's Office Administering Provider's Office (fill out information below) Patient Name (First, Last) Office/Hospital/Other Name Address Phone Fax Taltz® doses of 20 mg or 40 mg must be prepared and administered by a qualified Healthcare Provider using aseptic technique Prior Treatment Failures, Contraindications, Intolerances, or Allergies (select all that apply) No previous biologic or systemic agent Phototherapy BNBREL® STELARA® Other(s) signing below, I certify: 1) The therapy is medically necessary and that this information is accurate to the best of my knowledge; 2) I am disclosing this information to Eli Lilly and Company, Lilly USC, their affiliates, agents, representatives, business partners, and service providers (together "Lilly") to help enable treatment for this Patient; 3) The Patient is aware of, has consented to, and has of visclosure of their information to Lilly so that Lilly may contact the Patient to further enables ervices for those purposes and that such consent and direction applies to disclosurement from any third party for the support Lilly provides; and 5) I am licensed to prescribe the prescription medication identified in this form secrification complies with my state specific prescribing requirements and I appoint Lilly as my agent for the limited purposes of conveying this prescription by facsimile only to the dispensing pharma derstand that by signing this form, I am requesting support from Eli Lilly and Company for Patients receiving Taltz® pursuant to an FDA approved indication. PRESCRIBER SIGNATURE: PRESCRIBER PRESCRIBER.	lect a evice pe and	If > 50 kg (110 lbs) If 25 kg (55 lbs) to 50 kg (110lbs) If < 25 kg	Must select one: Prefilled syringe (80 mg/mL) 1mL inj Auto Injector (80 mg/mL) 1mL inj Must use: Prefilled syringe (80 mg/mL) 1mL inj Must use:	□ Starting Dose: 2 x 80 mg each (160 mg total) subcutaneous injection on Day 1 □ Maintenance Dose: 1 x 80 mg by subcutaneous injection every 4 weeks (thereafter) □ Starting Dose: 1 x 80 mg by subcutaneous injection Day 1 □ Maintenance Dose: 1 x 40 mg by subcutaneous injection every 4 weeks (thereafter) □ Starting Dose: 1 x 40 mg by subcutaneous injection Day 1 □ Maintenance Dose: 1 x 20 mg subcutaneous injection	2 pens/syringes 1 pen/syringe 1 syringe 1 syringe 1 syringe	28 28 28 28 28	0
Name (First, Last) Office/Hospital/Other Name Address Phone Fax Taltz® doses of 20 mg or 40 mg must be prepared and administered by a qualified Healthcare Provider using aseptic technique Prior Treatment Failures, Contraindications, Intolerances, or Allergies (select all that apply) Phototherapy ENBREL® STELARA® Other(s) Signing below, I certify: 1) The therapy is medically necessary and that this information is accurate to the best of my knowledge; 2) I am disclosing this information to Eli Lilly and Company, Lilly US (c, their affiliates, agents, representatives, business partners, and service providers (together "Lilly") to help enable treatment for this Patient; 3) The Patient is aware of, has consented to, and has of disclosure of their information to Lilly so that Lilly may contact the Patient to further enable services for those purposes and that such consent and direction applies to disclosures made through the ration of the Patient's therapy; 4) I will not seek reimbursement from any third party for the support Lilly provides; and 5) I am licensed to prescribe the prescription medication identified in this form derstand that by signing this form, I am requesting support from Eli Lilly and Company for Patients receiving Taltz® pursuant to an FDA approved indication. PRESCRIBER SIGNATURE: PRESCRI	lect a evice pe and osing	If > 50 kg (110 lbs) If 25 kg (55 lbs) to 50 kg (110 lbs) If < 25 kg (55 lbs)	Must select one: Prefilled syringe (80 mg/mL) 1mL inj Auto Injector (80 mg/mL) 1mL inj Must use: Prefilled syringe (80 mg/mL) 1mL inj Must use: Prefilled syringe (80 mg/mL) 1mL inj	□ Starting Dose: 2 x 80 mg each (160 mg total) subcutaneous injection on Day 1 □ Maintenance Dose: 1 x 80 mg by subcutaneous injection every 4 weeks (thereafter) □ Starting Dose: 1 x 80 mg by subcutaneous injection Day 1 □ Maintenance Dose: 1 x 40 mg by subcutaneous injection every 4 weeks (thereafter) □ Starting Dose: 1 x 40 mg by subcutaneous injection Day 1 □ Maintenance Dose: 1 x 20 mg subcutaneous injection	2 pens/syringes 1 pen/syringe 1 syringe 1 syringe 1 syringe	28 28 28 28 28	0
Office/Hospital/Other Name Address	evice pe and osing	If > 50 kg (110 lbs) If 25 kg (55 lbs) to 50 kg (110lbs) If < 25 kg (55 lbs) he below if t	Must select one: Prefilled syringe (80 mg/mL) 1mL inj Auto Injector (80 mg/mL) 1mL inj Must use: Prefilled syringe (80 mg/mL) 1mL inj Must use: Prefilled syringe (80 mg/mL) 1mL inj he patient weight is < 50 kg	□ Starting Dose: 2 x 80 mg each (160 mg total) subcutaneous injection on Day 1 □ Maintenance Dose: 1 x 80 mg by subcutaneous injection every 4 weeks (thereafter) □ Starting Dose: 1 x 80 mg by subcutaneous injection Day 1 □ Maintenance Dose: 1 x 40 mg by subcutaneous injection every 4 weeks (thereafter) □ Starting Dose: 1 x 40 mg by subcutaneous injection Day 1 □ Maintenance Dose: 1 x 20 mg subcutaneous injection every 4 weeks (thereafter)	2 pens/syringes 1 pen/syringe 1 syringe 1 syringe 1 syringe 1 syringe 1 syringe	28 28 28 28 28 28 28	0
Address	elect a evice pe and osing	If > 50 kg (110 lbs) If 25 kg (55 lbs) to 50 kg (110lbs) If < 25 kg (55 lbs) the below if the	Must select one: Prefilled syringe (80 mg/mL) 1mL inj Auto Injector (80 mg/mL) 1mL inj Must use: Prefilled syringe (80 mg/mL) 1mL inj Must use: Prefilled syringe (80 mg/mL) 1mL inj the patient weight is < 50 kg	□ Starting Dose: 2 x 80 mg each (160 mg total) subcutaneous injection on Day 1 □ Maintenance Dose: 1 x 80 mg by subcutaneous injection every 4 weeks (thereafter) □ Starting Dose: 1 x 80 mg by subcutaneous injection Day 1 □ Maintenance Dose: 1 x 40 mg by subcutaneous injection every 4 weeks (thereafter) □ Starting Dose: 1 x 40 mg by subcutaneous injection Day 1 □ Maintenance Dose: 1 x 40 mg by subcutaneous injection Day 1 □ Maintenance Dose: 1 x 20 mg subcutaneous injection every 4 weeks (thereafter) dministering Provider's Office (fill out information be	2 pens/syringes 1 pen/syringe 1 syringe 1 syringe 1 syringe 1 syringe 1 syringe	28 28 28 28 28 28 28	0
Phone	elect a evice pe and osing	If > 50 kg (110 lbs) If 25 kg (55 lbs) to 50 kg (110 lbs) If < 25 kg (55 lbs) he below if to be shi	Must select one: Prefilled syringe (80 mg/mL) 1mL inj Auto Injector (80 mg/mL) 1mL inj Must use: Prefilled syringe (80 mg/mL) 1mL inj Must use: Prefilled syringe (80 mg/mL) 1mL inj the patient weight is < 50 kg ipped to: Prescriber's Office Acome (First, Last)	□ Starting Dose: 2 x 80 mg each (160 mg total) subcutaneous injection on Day 1 □ Maintenance Dose: 1 x 80 mg by subcutaneous injection every 4 weeks (thereafter) □ Starting Dose: 1 x 80 mg by subcutaneous injection Day 1 □ Maintenance Dose: 1 x 40 mg by subcutaneous injection every 4 weeks (thereafter) □ Starting Dose: 1 x 40 mg by subcutaneous injection Day 1 □ Maintenance Dose: 1 x 20 mg subcutaneous injection every 4 weeks (thereafter) dministering Provider's Office (fill out information beginning to the provider of	2 pens/syringes 1 pen/syringe 1 syringe 1 syringe 1 syringe 1 syringe 1 syringe	28 28 28 28 28 28 28	0 0
Taltz® doses of 20 mg or 40 mg must be prepared and administered by a qualified Healthcare Provider using aseptic technique Prior Treatment Failures, Contraindications, Intolerances, or Allergies (select all that apply) No previous biologic or systemic agent Phototherapy ENBREL® STELARA® Other(s) Signing below, I certify: 1) The therapy is medically necessary and that this information is accurate to the best of my knowledge; 2) I am disclosing this information to Eli Lilly and Company, Lilly US C, their affiliates, agents, representatives, business partners, and service providers (together "Lilly") to help enable treatment for this Patient; 3) The Patient is aware of, has consented to, and has dy disclosure of their information to Lilly so that Lilly may contact the Patient to further enable services for those purposes and that such consent and direction applies to disclosures made through the scription of the Patient's therapy; 4) I will not seek reimbursement from any third party for the support Lilly provides; and 5) I am licensed to prescribe the prescription medication identified in this form and the patient is a my state specific prescribing requirements and I appoint Lilly as my agent for the limited purposes of conveying this prescription by facisinile only to the dispensing pharma iderstand that by signing this form, I am requesting support from Eli Lilly and Company for Patients receiving Taltz® pursuant to an FDA approved indication. PRESCRIBER SIGNATURE: PRESCRI	elect a evice ype and osing	If > 50 kg (110 lbs) If 25 kg (55 lbs) to 50 kg (110 lbs) If < 25 kg (55 lbs) he below if to be shi	Must select one: Prefilled syringe (80 mg/mL) 1mL inj Auto Injector (80 mg/mL) 1mL inj Must use: Prefilled syringe (80 mg/mL) 1mL inj Must use: Prefilled syringe (80 mg/mL) 1mL inj the patient weight is < 50 kg ipped to: Prescriber's Office Acome (First, Last) ice/Hospital/Other Name	□ Starting Dose: 2 x 80 mg each (160 mg total) subcutaneous injection on Day 1 □ Maintenance Dose: 1 x 80 mg by subcutaneous injection every 4 weeks (thereafter) □ Starting Dose: 1 x 80 mg by subcutaneous injection Day 1 □ Maintenance Dose: 1 x 40 mg by subcutaneous injection every 4 weeks (thereafter) □ Starting Dose: 1 x 40 mg by subcutaneous injection Day 1 □ Maintenance Dose: 1 x 20 mg subcutaneous injection every 4 weeks (thereafter) dministering Provider's Office (fill out information beginning to the provider of	2 pens/syringes 1 pen/syringe 1 syringe 1 syringe 1 syringe 1 syringe 1 syringe	28 28 28 28 28 28 28	0
Prior Treatment Failures, Contraindications, Intolerances, or Allergies (select all that apply) No previous biologic or systemic agent Phototherapy ENBREL® STELARA® Other(s)	elect a evice ype and osing	If > 50 kg (110 lbs) If 25 kg (55 lbs) to 50 kg (110lbs) If < 25 kg (55 lbs) the below if the	Must select one: Prefilled syringe (80 mg/mL) 1mL inj Auto Injector (80 mg/mL) 1mL inj Must use: Prefilled syringe (80 mg/mL) 1mL inj Must use: Prefilled syringe (80 mg/mL) 1mL inj the patient weight is < 50 kg ipped to: Prescriber's Office Acome (First, Last) ice/Hospital/Other Name	□ Starting Dose: 2 x 80 mg each (160 mg total) subcutaneous injection on Day 1 □ Maintenance Dose: 1 x 80 mg by subcutaneous injection every 4 weeks (thereafter) □ Starting Dose: 1 x 80 mg by subcutaneous injection Day 1 □ Maintenance Dose: 1 x 40 mg by subcutaneous injection every 4 weeks (thereafter) □ Starting Dose: 1 x 40 mg by subcutaneous injection Day 1 □ Maintenance Dose: 1 x 40 mg by subcutaneous injection Day 1 □ Maintenance Dose: 1 x 20 mg subcutaneous injection every 4 weeks (thereafter) dministering Provider's Office (fill out information be City	2 pens/syringes 1 pen/syringe 1 syringe 1 syringe 1 syringe 1 syringe 1 syringe 1 syringe	28 28 28 28 28 28 27 28	0
□ Phototherapy □ ENBREL® □ STELARA® □ Other(s)	elect a evice ype and osing ill out tl	If > 50 kg (110 lbs) If 25 kg (55 lbs) to 50 kg (110 lbs) If < 25 kg (55 lbs) he below if t uct to be shi Nair Offi Add Pho	Must select one: Prefilled syringe (80 mg/mL) 1mL inj Auto Injector (80 mg/mL) 1mL inj Must use: Prefilled syringe (80 mg/mL) 1mL inj Must use: Prefilled syringe (80 mg/mL) 1mL inj che patient weight is < 50 kg ipped to: Prescriber's Office Acome (First, Last) fice/Hospital/Other Name dress one	□ Starting Dose: 2 x 80 mg each (160 mg total) subcutaneous injection on Day 1 □ Maintenance Dose: 1 x 80 mg by subcutaneous injection every 4 weeks (thereafter) □ Starting Dose: 1 x 80 mg by subcutaneous injection Day 1 □ Maintenance Dose: 1 x 40 mg by subcutaneous injection every 4 weeks (thereafter) □ Starting Dose: 1 x 40 mg by subcutaneous injection Day 1 □ Maintenance Dose: 1 x 40 mg by subcutaneous injection Day 1 □ Maintenance Dose: 1 x 20 mg subcutaneous injection every 4 weeks (thereafter) dministering Provider's Office (fill out information becomes the provider of the pr	2 pens/syringes 1 pen/syringe 1 syringe 1 syringe 1 syringe 1 syringe 1 syringe 1 syringe State	28 28 28 28 28 28 28 27 28	0
r signing below, I certify: 1) The therapy is medically necessary and that this information is accurate to the best of my knowledge; 2) I am disclosing this information to Eli Lilly and Company, Lilly US (2, their affiliates, agents, representatives, business partners, and service providers (together "Lilly") to help enable treatment for this Patient; 3) The Patient is aware of, has consented to, and has dy disclosure of their information to Lilly so that Lilly may contact the Patient to further enable services for those purposes and that such consent and direction applies to disclosures made through the ration of the Patient's therapy; 4) I will not seek reimbursement from any third party for the support Lilly provides; and 5) I am licensed to prescribe the prescription medication identified in this form such parts and I appoint Lilly as my agent for the limited purposes of conveying this prescription by facsimile only to the dispensing pharma iderstand that by signing this form, I am requesting support from Eli Lilly and Company for Patients receiving Taltz® pursuant to an FDA approved indication. PRESCRIBER SIGNATURE: PRESCRI	elect a evice pe and osing lill out the Production Reference Taltz	If > 50 kg (110 lbs) If 25 kg (55 lbs) to 50 kg (110 lbs) If < 25 kg (55 lbs) he below if to be ship to be	Must select one: Prefilled syringe (80 mg/mL) 1mL inj Auto Injector (80 mg/mL) 1mL inj Must use: Prefilled syringe (80 mg/mL) 1mL inj Must use: Prefilled syringe (80 mg/mL) 1mL inj che patient weight is < 50 kg speed to: Prescriber's Office According to the patient weight in According to the prescriber's Office According to the patient weight in According to the According to the patient weight in According to the patient weigh	Starting Dose: 2 x 80 mg each (160 mg total) subcutaneous injection on Day 1 ☐ Maintenance Dose: 1 x 80 mg by subcutaneous injection every 4 weeks (thereafter) ☐ Starting Dose: 1 x 80 mg by subcutaneous injection Day 1 ☐ Maintenance Dose: 1 x 40 mg by subcutaneous injection every 4 weeks (thereafter) ☐ Starting Dose: 1 x 40 mg by subcutaneous injection Day 1 ☐ Maintenance Dose: 1 x 40 mg by subcutaneous injection Day 1 ☐ Maintenance Dose: 1 x 20 mg subcutaneous injection every 4 weeks (thereafter) dministering Provider's Office (fill out information be compared to the compare	2 pens/syringes 1 pen/syringe 1 syringe 1 syringe 1 syringe 1 syringe 1 syringe T syringe 1 syringe 1 syringe	28 28 28 28 28 28 27 28 28 28	0
C, their affiliates, agents, representatives, business partners, and service providers (together "Lilly") to help enable treatment for this Patient; 3) The Patient is aware of, has consented to, and has dy disclosure of their information to Lilly so that Lilly may contact the Patient to further enable services for those purposes and that such consent and direction applies to disclosures made through the ration of the Patient's therapy; 4) I will not seek reimbursement from any third party for the support Lilly provides; and 5) I am licensed to prescribe the prescribion medication identified in this form escription complies with my state specific prescribing requirements and I appoint Lilly as my agent for the limited purposes of conveying this prescription by facsimile only to the dispensing pharma iderstand that by signing this form, I am requesting support from Eli Lilly and Company for Patients receiving Taltz® pursuant to an FDA approved indication. PRESCRIBER SIGNATURE: PRESCRI	elect a evice pe and osing lill out the Production Taltz®	If > 50 kg (110 lbs) If 25 kg (55 lbs) to 50 kg (110 lbs) If < 25 kg (55 lbs) he below if to be ship to be	Must select one: Prefilled syringe (80 mg/mL) 1mL inj Auto Injector (80 mg/mL) 1mL inj Must use: Prefilled syringe (80 mg/mL) 1mL inj Must use: Prefilled syringe (80 mg/mL) 1mL inj Must use: Prefilled syringe (80 mg/mL) 1mL inj che patient weight is < 50 kg spped to: Prescriber's Office According to the patient weight in According to the patient weight is < 50 kg spped to: Prescriber's Office According to the patient weight is < 50 kg spped to: Prescriber's Office According to the patient weight is < 50 kg spped to: Prescriber's Office According to the patient weight is < 50 kg spped to: Prescriber's Office According to the patient weight is < 50 kg spped to: Prescriber's Office According to the patient weight is < 50 kg spped to: Prescriber's Office According to the patient weight is < 50 kg spped to: Prescriber's Office According to the patient weight is < 50 kg spped to: Prescriber's Office According to the patient weight is < 50 kg spped to: Prescriber's Office According to the patient weight is < 50 kg spped to: Prescriber's Office According to the patient weight is < 50 kg spped to: Prescriber's Office According to the patient weight is < 50 kg spped to: Prescriber's Office According to the patient weight is < 50 kg spped to: Prescriber's Office According to the patient weight is < 50 kg spped to: Prescriber's Office According to the patient weight is < 50 kg spped to: Prescriber's Office According to the patient weight is < 50 kg spped to: Prescriber's Office According to the patient weight is < 50 kg spped to: Prescriber's Office According to the patient weight is < 50 kg spped to: Prescriber's Office According to the patient weight is < 50 kg spped to: Prescriber's Office According to the patient weight is < 50 kg spped to: Prescriber's Office According to the patient weight is < 50 kg spped to: Prescriber's Office According to the patient weight is < 50 kg spped to: Prescriber's Office According to the patient weight is < 50 kg spped to: Prescriber's Office According to t	Starting Dose: 2 x 80 mg each (160 mg total) subcutaneous injection on Day 1 Maintenance Dose: 1 x 80 mg by subcutaneous injection every 4 weeks (thereafter) Starting Dose: 1 x 80 mg by subcutaneous injection Day 1 Maintenance Dose: 1 x 40 mg by subcutaneous injection Day 1 Starting Dose: 1 x 40 mg by subcutaneous injection Day 1 Starting Dose: 1 x 40 mg by subcutaneous injection Day 1 Maintenance Dose: 1 x 20 mg subcutaneous injection every 4 weeks (thereafter) dministering Provider's Office (fill out information be compared to the provider of	2 pens/syringes 1 pen/syringe 1 syringe 1 syringe 1 syringe 1 syringe 1 syringe T syringe 1 syringe 1 syringe	28 28 28 28 28 28 27 28 28 28	0
uration of the Patient's therapy; 4) I will not seek reimbursement from any third party for the support Lilly provides; and 5) I am licensed to prescribe the prescription medication identified in this for rescription complies with my state specific prescribing requirements and I appoint Lilly as my agent for the limited purposes of conveying this prescription by facsimile only to the dispensing pharma nderstand that by signing this form, I am requesting support from Eli Lilly and Company for Patients receiving Taltz® pursuant to an FDA approved indication. PRESCRIBER SIGNATURE: PRESCRI UIST MANUALLY SIGN AND DATE. Rubber stamps, signature by other office personnel for the Prescriber, and computer-generated signatures will not be accepted.	elect a evice pe and osing lill out the Production Taltz Prior T	If > 50 kg (110 lbs) If 25 kg (55 lbs) to 50 kg (110 lbs) If < 25 kg (55 lbs) he below if t uct to be shi Nar Offf Add Pho doses of 20 Treatment Fai totherapy E	Must select one: Prefilled syringe (80 mg/mL) 1mL inj Auto Injector (80 mg/mL) 1mL inj Must use: Prefilled syringe (80 mg/mL) 1mL inj Must use: Prefilled syringe (80 mg/mL) 1mL inj the patient weight is < 50 kg ipped to: Prescriber's Office Ac me (First, Last) fice/Hospital/Other Name dress one 0 mg or 40 mg must be prepared and illures, Contraindications, Intolerances, of ENBREL® STELARA® Other(s)	Starting Dose: 2 x 80 mg each (160 mg total) subcutaneous injection on Day 1 ☐ Maintenance Dose: 1 x 80 mg by subcutaneous injection every 4 weeks (thereafter) ☐ Starting Dose: 1 x 80 mg by subcutaneous injection Day 1 ☐ Maintenance Dose: 1 x 40 mg by subcutaneous injection Day 1 ☐ Maintenance Dose: 1 x 40 mg by subcutaneous injection Day 1 ☐ Maintenance Dose: 1 x 20 mg subcutaneous injection Day 1 ☐ Maintenance Dose: 1 x 20 mg subcutaneous injection every 4 weeks (thereafter) dministering Provider's Office (fill out information become defined by a qualified Healthcare Provider or Allergies (select all that apply) ☐ No previous biology	2 pens/syringes 1 pen/syringe 1 syringe 1 syringe 1 syringe 1 syringe 2 syringe 1 syringe 1 syringe 1 syringe 1 syringe 1 syringe	28	0
nderstand that by signing this form, I am requesting support from Eli Lilly and Company for Patients receiving Taltz® pursuant to an FDA approved indication. PRESCRIBER SIGNATURE: PRESCRI	elect a evice pe and osing lill out the Production of Taltz® Prior T Photo y signing b C, their af	If > 50 kg (110 lbs) If 25 kg (55 lbs) to 50 kg (110 lbs) If < 25 kg (55 lbs) he below if the below, I certify: 1) ffiliates, agents, in the below if the below, I certify: 1) ffiliates, agents, in the below if the below, I certify: 1) ffiliates, agents, in the below if the below, I certify: 1) ffiliates, agents, in the below if	Must select one: Prefilled syringe (80 mg/mL) 1mL inj Auto Injector (80 mg/mL) 1mL inj Must use: Prefilled syringe (80 mg/mL) 1mL inj Must use: Prefilled syringe (80 mg/mL) 1mL inj the patient weight is < 50 kg ipped to: Prescriber's Office Ac me (First, Last) fice/Hospital/Other Name dress one 0 mg or 40 mg must be prepared and illures, Contraindications, Intolerances, of ENBREL® STELARA® Other(s)) The therapy is medically necessary and that this ir representatives, business partners, and service pro	Starting Dose: 2 x 80 mg each (160 mg total) subcutaneous injection on Day 1 Maintenance Dose: 1 x 80 mg by subcutaneous injection every 4 weeks (thereafter) Starting Dose: 1 x 80 mg by subcutaneous injection Day 1 Maintenance Dose: 1 x 40 mg by subcutaneous injection Day 1 Maintenance Dose: 1 x 40 mg by subcutaneous injection Day 1 Starting Dose: 1 x 40 mg by subcutaneous injection Day 1 Maintenance Dose: 1 x 20 mg subcutaneous injection Day 1 Maintenance Dose: 1 x 20 mg subcutaneous injection every 4 weeks (thereafter) dministering Provider's Office (fill out information be compared to the period of	2 pens/syringes 1 pen/syringe 1 syringe 1 syringe 1 syringe 1 syringe 1 syringe rusing aseptic togic or systemic ages ages this information to Earlier Patient is aware of the Patient is aware of	28 28 28 28 28 28 28 2technique gent Lilly and Compar f, has consented to,	0 0 0 uy, Lilly USA and has di
THE RESERVE THE PARTY OF THE PA	elect a evice pe and osing lill out the Production of Taltz® Prior T Photo y signing b C., their af y disclosu uration of the prior of	If 25 kg (110 lbs) If 25 kg (55 lbs) to 50 kg (110 lbs) If 25 kg (55 lbs) If < 25 kg (55 lbs) he below if t uct to be shi Nai Offi Add Pho doses of 20 Treatment Fai totherapy Evelow, I certify: 1) offiliates, agents, re of their inform the Patient's ther	Must select one: Prefilled syringe (80 mg/mL) 1mL inj Auto Injector (80 mg/mL) 1mL inj Must use: Prefilled syringe (80 mg/mL) 1mL inj Must use: Prefilled syringe (80 mg/mL) 1mL inj Must use: Prefilled syringe (80 mg/mL) 1mL inj Che patient weight is < 50 kg Che patient weight is	Starting Dose: 2 x 80 mg each (160 mg total) subcutaneous injection on Day 1 Maintenance Dose: 1 x 80 mg by subcutaneous injection every 4 weeks (thereafter) Starting Dose: 1 x 80 mg by subcutaneous injection Day 1 Maintenance Dose: 1 x 40 mg by subcutaneous injection every 4 weeks (thereafter) Starting Dose: 1 x 40 mg by subcutaneous injection every 4 weeks (thereafter) Starting Dose: 1 x 40 mg by subcutaneous injection Day 1 Maintenance Dose: 1 x 20 mg subcutaneous injection every 4 weeks (thereafter) City Fax d administering Provider's Office (fill out information be City Fax d administered by a qualified Healthcare Provider or Allergies (select all that apply) □ No previous biolog information is accurate to the best of my knowledge; 2) I am disclosing oviders (together "Lilly") to help enable treatment for this Patient; 3) To of urther enable services for those purposes and that such consent ar dr party for the support Lilly provides; and 5) I am licensed to prescrit	2 pens/syringes 1 pen/syringe 1 syringe 1 syringe 1 syringe 1 syringe 1 syringe The Patient is aware of and direction applies to be the prescription me	28 28 28 28 28 28 28 21 28 28 21 28 21 28 21 28 21 28 28 28 28 28 28 28 28 28 28 28 28 28	0 0 0 uny, Lilly US/ and has di



Not signing this form will result in an incomplete submission and a delay in requested services



PP-RC-US-2030 12/2023 ©Lilly USA, LLC 2023. All rights reserved.

PUBLISHED 12/2023

Privacy Notice:

We may use and save your personal information (PI) to meet legal or regulatory obligations that are in the legitimate interest of Lilly, to fulfill legitimate and lawful business purposes in accordance with Lilly's record retention policies and applicable laws and regulations, and to respond to lawful requests by public authorities, including to comply with national security or law enforcement requests.

Some of this PI may be considered sensitive under applicable laws, such as information about your health or medical diagnosis and demographic information collected in some circumstances, such as race, ethnic origin, and sexual orientation. We may process your sensitive PI with your consent, or as otherwise permitted by law.

We may de-identify certain of the information described above. To the extent we maintain and use-de-identified information in its de-identified form, and do not re-identify such information except as permitted by law, this de-identified information is not PI and is not subject to this Notice. Where permitted by law, Lilly may also enhance or merge information, including PI, with information obtained from third parties for the same purposes shared above. PI may also be used for profiling for the same purposes shared above. You may object to profiling via automated decision making by contacting us using the information in the "How to Contact Us" section below.

Your information may be combined with other information that you have previously provided or that Lilly has received. We do not sell personal information.

We may transmit personal information about you to other Lilly affiliates worldwide. These affiliates may in turn transmit personal information about you to other Lilly affiliates. Some of Lilly's affiliates may be located in countries that do not ensure the same level of data protection. Nevertheless, all of Lilly's affiliates are required to treat personal information in a manner consistent with this notice. To obtain additional information about Lilly's privacy practices, including the basis for transfers and safeguards that Lilly has in place for cross-border transfers of personal information, please contact us at privacy@lilly.com or visit https://privacynotice.lilly.com.

We provide reasonable physical, electronic, and procedural safeguards to protect information we work with and maintain. We limit access to your information to authorized employees, agents, contractors, vendors, subsidiaries, and business partners, or others who need such access to information to carry out their assigned roles and responsibilities on behalf of Lilly. Please be aware, although we try to protect the information we work with and maintain, no security system can prevent all potential security breaches.

Upon verification, you have the right to request information from us regarding how your personal information is being used and with whom that information is being shared. You also have the right to request to see and get a copy of the personal information that we have about you, request its correction, or request its erasure/deletion.

There may be exceptions that apply to your request.

In limited circumstances, you may have the right to have your information transmitted to another entity or person in a machine-readable format.

To exercise your rights, you or your authorized representative may submit a request by contacting us using one of the methods listed below.

You may make any of the above requests by contacting us at: The Lilly Answers Center, Lilly USA, LLC, Lilly Corporate Center, Indianapolis, IN 46285 or by calling 1-800-545-5979.

If you wish to raise a complaint on how we have handled your personal information, you can contact the Global Privacy Office and Data Protection Officer at privacy@ lilly.com who will investigate the matter.

If you are not satisfied with our response or have any concerns about how your data is being processed, you can register a complaint with a relevant regulatory authority (e.g., a Data Protection Authority (DPA) or Attorney General).

You may be entitled, in accordance with applicable law, to appeal a refusal to take action on your request. To do so, please contact us by using one of the methods listed in this document.

You will not be discriminated against for exercising any of your rights.

California Privacy Disclosures

California residents who have an established business relationship with Lilly <u>may have</u> the right to request information regarding Lilly's disclosure of certain PI to Third Parties for their direct marketing purposes. To make a request for such information, you may contact us using the information in this document.

Sale and Sharing of Personal Information

Lilly does not sell PI about California consumers that are protected under the California Consumer Privacy Act of 2018 ("CCPA") or California Privacy Rights Act ("CPRA") to third parties or share such PI with third parties for targeted or cross-context behavioral advertising, as those terms are defined by applicable law. When Lilly permits third parties to collect PI through our websites or discloses PI to third parties, Lilly is doing so pursuant to various exceptions to the opt-out rights provided for under California law. For example, Lilly permits third parties acting on its behalf to process PI for the business purposes described in this Notice including advertising and marketing services (excluding cross-context behavioral advertising). In addition, Lilly may permit third-party advertising solutions to process PI when you direct us to do so by agreeing to the use of such technologies to personalize Lilly's content and ads. Consistent with the above, Lilly does not sell or share for cross-context behavioral advertising PI relating to consumers who it knows are under 16 years of age.

Sensitive Personal Information

Lilly does not use or disclose your sensitive PI except for limited purposes that are authorized by law. For example, Lilly may collect information about your health or medical diagnosis to provide you specific functionality or products or services that you have requested. California law does not afford you rights to limit the use or disclosure of sensitive PI for these purposes, although we may nonetheless ask for your consent or provide you choices about how we use this information depending on the relevant context.

PP-RC-US-2030 12/2023 ©Lilly USA, LLC 2023. All rights reserved.

 $Taltz^{\circledcirc}, its \ delivery \ device \ base, \ and \ Taltz \ Together^{\blacksquare} \ are \ trademarks \ owned \ or \ licensed \ by \ Eli \ Lilly \ and \ Company, \ its \ subsidiaries, \ or \ affiliates.$

All product names and trademarks are the property of their respective trademark owners.

